Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | IKBKB | O14920 | 2/20 | 0.37 |
| ▸ | CHUK | O15111 | 2/20 | 0.37 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.36 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.34 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244250 | 1.00 | CYP3A4 (0.49) | CYP3A4TRPV1IKBKBCHUKPIP4K2A | |
| SCHEMBL6832450 | 0.84 | CYP19A1 (0.34) | CYP3A4TRPV1MEN1KMT2A | |
| SCHEMBL2489135 | 0.83 | CYP3A4 (0.49) | CYP3A4TRPV1IKBKBCHUK | |
| SCHEMBL2489133 | 0.83 | CYP3A4 (0.49) | CYP3A4TRPV1IKBKBCHUK | |
| SCHEMBL1543239 | 0.82 | CYP3A4 (0.68) | CYP3A4TRPV1IKBKBCHUKPIP4K2A | |
| SCHEMBL1543237 | 0.82 | CYP3A4 (0.68) | CYP3A4TRPV1IKBKBCHUKPIP4K2A | |
| SCHEMBL2491324 | 0.81 | CYP3A4 (0.72) | CYP3A4TRPV1IKBKBCHUKPIP4K2A | |
| SCHEMBL2491321 | 0.81 | CYP3A4 (0.72) | CYP3A4TRPV1IKBKBCHUKPIP4K2A | |
| SCHEMBL1348089 | 0.79 | CYP3A4 (0.48) | CYP3A4TRPV1IKBKBCHUKPIP4K2A | |
| SCHEMBL1348091 | 0.79 | CYP3A4 (0.48) | CYP3A4TRPV1IKBKBCHUKPIP4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | claimed |
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | CYP3A4 978/4885TRPV1 4760/4885IKBKB 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.